Graphite Bio, Inc. Profile Avatar - Palmy Investing

Graphite Bio, Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly co…

Biotechnology
US, South San Francisco [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Graphite Bio, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Graphite Bio, Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Graphite Bio, Inc..

End of GRPH's Analysis
CIK: 1815776 CUSIP: 38870X104 ISIN: US38870X1046 LEI: - UEI: -
Secondary Listings
GRPH has no secondary listings inside our databases.